Pharvaris B.V. reported Phase II data on 6 December for its oral candidate for hereditary angioedema that both it and analysts are saying suggest biologic-like efficacy with the convenience of oral therapy. The catch? Pharvaris needs to get a US Food and Drug Administration hold lifted before it can try to set up an end-of-Phase II meeting with the agency and initiate a Phase III program.
Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo
The Swiss firm reported that its oral bradykinin B2 receptor antagonist reduced monthly hereditary angioedema attacks by 84.5% compared with placebo, suggesting biologic-like efficacy with an oral drug.
More from Clinical Trials
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.